For comparison, Pfizer reported yesterday that Abrysvo made full-year sales of $890 million, which - while respectable - were well below its competitor. However, it brought in $515 million in the ...

An alternative to the antibody therapies is Pfizer's RSV vaccine Abrysvo, which is approved for maternal immunisation to prevent disease in newborns and infants, as well as for use in older adults ...

new launches like Abrysvo, newly acquired products like Nurtec as well as those acquired from Seagen (December 2023). The trend is expected to continue in the fourth quarter and probably in 2025.

(NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF ...

Anyone aged between 75 and 79 is eligible for one dose of Pfizer's jab Abrysvo to tackle RSV. All women who are at least 28 weeks pregnant are also being invited for a shot to help keep themsel ...

Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches ...

In 1914, a newspaper claimed that, guided by a “fury of logic” to reconstitute the past, Viollet-le-Duc “delivered a cathedral which had never existed, at any time”. His rehabilitation ...

Punjab Chief Minister Maryam Nawaz Sharif has approved reconstitution of District Peace Committees across the province. In line with this decision, Punjab Home Department has issued a directive to ...

Employers Shift to Equity-Focused Strategies as Health Costs Outpace Wages ...